Cambridge, Massachusetts-based Crossbow Therapeutics announced a $80M Series A to develop antibody therapies for cancers.

 

Cambridge, Massachusetts-based Crossbow Therapeutics announced a $80M Series A to develop antibody therapies for cancers.  The round was led by MPM BioImpact and Pfizer, with participation from Eli Lilly, Polaris Partners, and Mirae Asset Venture Investment, among others. Crossbow develops therapies that mimic T-cell receptors that could potentially target peptide-loaded major histocompatibility complexes on cancer cells. The biotech startup is led by Dr. Briggs Morrison, who worked for over 30 years at companies such as AstraZeneca, Pfizer, and Merck. Crossbow's Chief Scientific Officer, Dmitri Wiederschain, previously worked at Jounce Therapeutics and Novartis.